OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been given an average recommendation of “Reduce” by the five brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $1.55.

A number of research analysts have issued reports on the stock. Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Finally, Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently made changes to their positions in OPK. Cubist Systematic Strategies LLC grew its stake in shares of OPKO Health by 2,369.9% in the first quarter. Cubist Systematic Strategies LLC now owns 119,223 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 114,396 shares in the last quarter. AQR Capital Management LLC increased its position in shares of OPKO Health by 466.7% during the first quarter. AQR Capital Management LLC now owns 1,608,906 shares of the biotechnology company’s stock worth $2,671,000 after acquiring an additional 1,324,988 shares during the period. Millennium Management LLC increased its position in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. boosted its holdings in OPKO Health by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock valued at $6,642,000 after purchasing an additional 161,394 shares during the period. Finally, Caxton Associates LLP purchased a new position in OPKO Health in the first quarter valued at $130,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Price Performance

OPKO Health stock opened at $1.22 on Monday. OPKO Health has a 12-month low of $0.98 and a 12-month high of $1.61. The company has a current ratio of 3.61, a quick ratio of 3.17 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.26. The firm has a market capitalization of $921.21 million, a PE ratio of -4.52 and a beta of 1.48.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. During the same period last year, the company earned ($0.10) EPS. OPKO Health’s quarterly revenue was down 17.1% compared to the same quarter last year. As a group, equities research analysts forecast that OPKO Health will post -0.29 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.